J Cancer 2016; 7(13):1901-1906. doi:10.7150/jca.15802

Research Paper

The Efficacy of Bevacizumab in Different Line Chemotherapy for Chinese Patients with Metastatic Colorectal Cancer

Chenxi Yin1,2,3*, Gang Ma1,2,3*, Yuming Rong1,2,4, Pengfei Kong1,2,4, Qiong Yang1,2,4, Chang Jiang1,2,4, Fangxin Liao1,2,4, Bei Zhang1,2,4, Wenzhuo He1,2,4✉, Liangping Xia1,2,4✉

1. State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, R.P. China;
2. Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, 510060, R.P. China;
3. ICU, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, R.P. China;
4. VIP Region, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, R.P. China.
* contributed equally to this paper.

Abstract

Objective: To evaluate the effect of bevacizumab in different lines for Chinese patients with metastatic colorectal cancer (mCRC).

Methods: Patients of mCRC treated with bevacizumab or not at Sun Yat-sen University Cancer Center from 2007 to 2013 were recruited as study and control group. Endpoints were overall survival (OS), progression free survival (PFS), objective response rate (ORR) and disease control rate (DCR). Corresponding survival rates of first- and second-line in study and control group were compared.

Results: 1. Median OS of study and control group were 44.8 (95% CI: 37.1~52.4) months, 36.1 (95% CI: 32.8~39.5) months respectively, which were significantly different (P=0.004). 2. In the first line treatment, median OS of study and control group were 49.9(95% CI: 40.1~59.8) months and 36.1 (95% CI: 32.7~39.4) months (P=0.002), respectively. And median PFS were 10.1(95% CI: 8.7~11.5) months and 6.2 (95% CI: 5.5~6.8) months (P<0.001), respectively. 3. In the second line treatment, median OS of study and control group were 34.8 (95% CI: 26.3~43.3) months and 24.6 (95% CI: 22.2~27.0) months (P=0.022), respectively. And the mPFS were 6.3 (95% CI: 4.7~7.8) months and 3.1 (95% CI: 2.5~3.6) months (P<0.001), respectively. 4. Median OS of first- and second-line treatment of the study groups were 49.9(95% CI: 40.1~59.8) months and 34.8 (95% CI: 26.3~43.3) months (P=0.189), respectively.

Conclusion: The combination of bevacizumab and chemotherapy had a promising efficacy in Chinese mCRC patients. However, their OS were statistically insignificant between first- and second-line of bevacizumab groups.

Keywords: bevacizumab, chemotherapy line setting, mCRC, efficacy.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.
How to cite this article:
Yin C, Ma G, Rong Y, Kong P, Yang Q, Jiang C, Liao F, Zhang B, He W, Xia L. The Efficacy of Bevacizumab in Different Line Chemotherapy for Chinese Patients with Metastatic Colorectal Cancer. J Cancer 2016; 7(13):1901-1906. doi:10.7150/jca.15802. Available from http://www.jcancer.org/v07p1901.htm